Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: Public health implications

Genetics in Medicine

Volumn 7, Issue 1, 2005, Pages 28-33

  McClain, Monica R ^a   Palomaki, Glenn E ^a   Nathanson, Katherine L ^b   Haddow, James E ^a  

^a FOUNDATION FOR BLOOD RESEARCH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BRCA mutations; Breast cancer; Genetics; Public health

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; DNA SEQUENCE; EPIDEMIOLOGICAL DATA; FEMALE; GENE MUTATION; GENETIC RISK; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; PENETRANCE; PROBABILITY; PUBLIC HEALTH; RISK ASSESSMENT;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PENETRANCE; PREVALENCE; RISK FACTORS;

EID: 12144274336     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GIM.0000151155.36470.FF     Document Type: Article

References (51)

1. Genetic susceptibility to breast and ovarian cancer: assessment, counseling and testing guidelines. American College of Medical Genetics Foundation. Available at: http://www.health.state.ny.us/nysdoh/cancer/obcancer/ contents.htm. Accessed September 10, 2004.
2. Advice about familial aspects of breast cancer and ovarian cancer: A guide for health professionals: National Health and Medical Research Council, National Breast Cancer Centre; 2000. Available at: http://www.nbcc.org.au. Accessed September 10, 2004.
3. Elwyn G, Iredale R, Gray J. Reactions of GPs to a triage-controlled referral system for cancer genetics. Fam Pract 2002;19:65-71.
4. Lucassen A, Watson E, Harcourt J et al. Guidelines for referral to a regional genetics service: GPs respond by referring more appropriate cases. Fam Pract 2001;18:135-140.
5. American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. J Clin Oncol 2003;11:11.
6. Genetic/familial high-risk assessment: breast and ovarian. Jenkintown, Pa: National Comprehensive Cancer Network; 2003. Available at: http://www.nccn.org. Accessed September 10, 2004.
7. Rose PW, Watson E, Yudkin P et al. Referral of patients with a family history of breast/ovarian cancer-GPs' knowledge and expectations. Fam Pract 2001;18:487-490.
8. Wideroff L, Freedman AN, Olson L et al. Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev 2003; 12:295-303.
9. Sifri R, Myers R, Hyslop T et al. Use of cancer susceptibility testing among primary care physicians. Clin Genet 2003;64:355-360.
10. Mouchawar J, Klein CE, Mullineaux L. Colorado family physicians' knowledge of hereditary breast cancer and related practice. J Cancer Educ Spring 2001;16:33-37.
11. Friedman LC, Cooper HP, Webb JA, Weinberg AD, Pion SE. Primary care physicians' attitudes and practices regarding cancer genetics: a comparison of 2001 with 1996 survey results. J Cancer Educ 2003;18:91-94.
12. Hereditary risk of breast and ovarian cancer. A professional and community education program. Salt Lake City: Myriad Genetic Laboratories; 2001. Available at: http://www.myriad.com. Accessed September 10, 2004.
13. Identifying and managing hereditary risk for breast and ovarian cancer. Chicago, Ill: American Medical Association; 2001. Available at: http://www.ama-assn.org. Accessed September 10, 2004.
14. Genetics of breast and ovarian cancer (PDQ). National Cancer Institute. 6/10/04. Available at: http://www.cancer.gov/cancerinfo/pdq/genetics/breast-and- ovarian. Accessed September 10, 2004.
15. Petrucelli MS, Daly MB, Burke W et al. BRCA1 and BRCA2 hereditary breast/ovarian cancer. 09/03/04. Available at: http://www.genetests.org. Accessed September 10, 2004.
16. Fodor FH, Weston A, Bleiweiss IJ et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998;63:45-51.
17. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 1999;64:963-970.
18. Oddoux C, Struewing JP, Clayton CM et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14:188-190.
19. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-187.
20. Struewing JP, Abeliovich D, Peretz T et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet Oct 1995;11:198-200.
21. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med May 15 1997;336:1401-1408.
22. DevCan software: Probability of developing or dying of cancer [computer program]. Version 5.1: Statistical Research and Application Branch, National Cancer Institute; 2003. Available at: http://srab.cancer.gov/devcan. Accessed September 10, 2004.
23. Fay MP, Pfeiffer R, Cronin KA, Le C, Feuer EJ. Age-conditional probabilities of developing cancer. Stat Med 2003;22:1837-1848.
24. Hopper JL, Southey MC, Dite GS et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999;8:741-747.
25. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer. 2000; 83:1301-1308.
26. Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 2001;93:1215-1223.
27. Malone KE, Daling JR, Neal C et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 2000;88:1393-1402.
28. Peto J, Collins N, Barfoot R et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999;91:943-949.
29. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998;279:915-921.
30. Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer 2000;36:1200-1208.
31. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496-504.
32. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457-1462.
33. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-2324.
34. Newman B, Millikan RC, King MC. Genetic epidemiology of breast and ovarian cancers. Epidemiol Rev 1997;19:69-79.
35. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130.
36. Antoniou AC, Pharoah PD, McMullan G et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002;86:76-83.
37. Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. Genet Epidemiol 2000;18:173-190.
38. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-1372.
39. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56: 265-271.
40. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-695.
41. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-689.
42. Risch HA, McLaughlin JR, Cole DE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-710.
43. Schubert EL, Lee MK, Mefford HC et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 1997;60:1031-1040.
44. Scott CL, Jenkins MA, Southey MC et al. Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics. Hum Genet 2003;112:542-551.
45. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2002;94:1221-1226.
46. Gayther SA, Mangion J, Russell P et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997; 15:103-105.
47. Neuhausen SL, Godwin AK, Gershoni-Baruch R et al. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 1998;62:1381-1388.
48. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410-419.
49. Thompson D, Easton D. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 2002;11:329-336.
50. Eng C, Brody LC, Wagner TM et al. Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet 2001;38:824-833.
51. Gross E, Arnold N, Goette J, Schwarz-Boeger U, Kiechle M. A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet 1999;105: 72-78.